Pablo Avilés

1.8k total citations
72 papers, 888 citations indexed

About

Pablo Avilés is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pablo Avilés has authored 72 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 27 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pablo Avilés's work include Cancer therapeutics and mechanisms (14 papers), Cancer Treatment and Pharmacology (10 papers) and Synthesis and Biological Activity (8 papers). Pablo Avilés is often cited by papers focused on Cancer therapeutics and mechanisms (14 papers), Cancer Treatment and Pharmacology (10 papers) and Synthesis and Biological Activity (8 papers). Pablo Avilés collaborates with scholars based in Spain, Belgium and Netherlands. Pablo Avilés's co-authors include Carlos M. Galmarini, Juan Fernando Martínez-Leal, Carmen Cuevas, María José Guillén, Jean‐Marc Egly, Frédéric Coin, Emmanuel Compe, Gema Santamaría Núñez, Carlos Mario Genes Robles and Carlos Gimeno Verdejo and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Pablo Avilés

65 papers receiving 869 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pablo Avilés Spain 17 347 282 154 142 131 72 888
Wuli Zhao China 22 658 1.9× 206 0.7× 159 1.0× 67 0.5× 82 0.6× 52 1.2k
Witold Lasek Poland 19 415 1.2× 564 2.0× 161 1.0× 111 0.8× 89 0.7× 50 1.4k
Nidhi Gupta India 23 580 1.7× 302 1.1× 207 1.3× 93 0.7× 43 0.3× 72 1.3k
Prasanthi Karna United States 16 629 1.8× 214 0.8× 255 1.7× 75 0.5× 34 0.3× 21 1.2k
Kulthida Vaeteewoottacharn Thailand 22 724 2.1× 553 2.0× 401 2.6× 136 1.0× 68 0.5× 90 1.7k
Somesh Sharma India 22 648 1.9× 235 0.8× 97 0.6× 112 0.8× 27 0.2× 62 1.4k
Ida Silvestri Italy 20 475 1.4× 412 1.5× 202 1.3× 200 1.4× 75 0.6× 46 1.1k
Xiujun Liu China 18 472 1.4× 268 1.0× 72 0.5× 60 0.4× 36 0.3× 61 832
Jingwen Wang China 14 521 1.5× 162 0.6× 179 1.2× 76 0.5× 37 0.3× 70 803
İlker Dıbırdık United States 17 536 1.5× 293 1.0× 152 1.0× 42 0.3× 44 0.3× 42 1.3k

Countries citing papers authored by Pablo Avilés

Since Specialization
Citations

This map shows the geographic impact of Pablo Avilés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Avilés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Avilés more than expected).

Fields of papers citing papers by Pablo Avilés

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Avilés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Avilés. The network helps show where Pablo Avilés may publish in the future.

Co-authorship network of co-authors of Pablo Avilés

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Avilés. A scholar is included among the top collaborators of Pablo Avilés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Avilés. Pablo Avilés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Avilés, Pablo, Luis A. García-Astudillo, Luis Entrena, et al.. (2024). Hardening Architectures for Multiprocessor System-on-Chip. IEEE Transactions on Nuclear Science. 71(8). 1887–1895. 1 indexed citations
2.
Avilés, Pablo, et al.. (2024). Hybrid Hardening Approach for a Fault-Tolerant RISC-V System-On-Chip. IEEE Transactions on Nuclear Science. 71(8). 1722–1730.
3.
Avilés, Pablo, Jose A. Belloch, Luis Entrena, & Almudena Lindoso. (2023). Supervised Triple Macrosynchronized Lockstep (STMLS) Architecture for Multicore Processors. IEEE Access. 11. 128706–128723.
4.
Woźniak, Agnieszka, Jasmien Cornillie, Pablo Avilés, et al.. (2022). Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. International Journal of Molecular Sciences. 23(13). 7454–7454. 3 indexed citations
5.
Avilés, Pablo, Almudena Lindoso, Jose A. Belloch, et al.. (2021). Radiation Testing of a Multiprocessor Macrosynchronized Lockstep Architecture With FreeRTOS. IEEE Transactions on Nuclear Science. 69(3). 462–469. 18 indexed citations
6.
Woźniak, Agnieszka, Jasmien Wellens, Yemarshet K. Gebreyohannes, et al.. (2020). Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. Translational Oncology. 13(11). 100832–100832. 14 indexed citations
7.
Losada, Alejandro, Juan José Berlanga, Antonio Jiménez-Ruı́z, et al.. (2019). Generation of endoplasmic reticulum stress and inhibition of autophagy by plitidepsin induces proteotoxic apoptosis in cancer cells. Biochemical Pharmacology. 172. 113744–113744. 28 indexed citations
8.
Rosing, Hilde, Rubin Lubomirov, Pablo Avilés, et al.. (2018). Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158. 160–165. 5 indexed citations
9.
Galmarini, Carlos M., Maud Martin, Benjamin Pierre Bouchet, et al.. (2018). Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. BMC Cancer. 18(1). 164–164. 27 indexed citations
10.
Roland, Joseph T., Susan M. Kitchen-Goosen, Elissa A. Boguslawski, et al.. (2016). Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Research. 76(22). 6657–6668. 68 indexed citations
11.
Núñez, Gema Santamaría, Carlos Mario Genes Robles, Juan Fernando Martínez-Leal, et al.. (2016). Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. Molecular Cancer Therapeutics. 15(10). 2399–2412. 114 indexed citations
12.
13.
Lollo, Giovanna, Pablo Hervella, Pilar Calvo, et al.. (2015). Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative. International Journal of Pharmaceutics. 483(1-2). 212–219. 28 indexed citations
14.
Oliveira, Hugo, Julie Thévenot, Élisabeth Garanger, et al.. (2013). Nano-Encapsulation of Plitidepsin: In Vivo Pharmacokinetics, Biodistribution, and Efficacy in a Renal Xenograft Tumor Model. Pharmaceutical Research. 31(4). 983–991. 20 indexed citations
15.
Martínez-Leal, Juan Fernando, Victoria Moneo, Alberto Domingo, et al.. (2009). Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines. Biochemical Pharmacology. 78(2). 162–170. 54 indexed citations
16.
Vermeir, Marc, Alex Hemeryck, Filip Cuyckens, et al.. (2009). In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping. Biochemical Pharmacology. 77(10). 1642–1654. 18 indexed citations
17.
LePage, Doreen, Halina Sasak, María José Guillén, et al.. (2007). Antitumor activity of Zalypsis® (PM00104) in experimental models of bladder, gastric and liver cancer.. Molecular Cancer Therapeutics. 6. 5 indexed citations
18.
Avilés, Pablo, Teresa L. Wright, María José Guillén, et al.. (2006). Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs. Cancer Research. 66. 728–728. 2 indexed citations
19.
Avilés, Pablo, et al.. (2003). Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of Aplidin®, a novel marine‐derived antineoplastic agent, in human plasma. Rapid Communications in Mass Spectrometry. 17(16). 1909–1914. 10 indexed citations
20.
Ávila, O., Mercedes Rodríguez‐Villafuerte, I. Gamboa‐deBuen, et al.. (2002). On the Correct Measurement of Relative Heavy Charged Particles to Gamma Thermoluminescent Efficiencies. Radiation Protection Dosimetry. 100(1). 87–90. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wuli Zhao Breakdown of academic impact, for papers by Witold Lasek Breakdown of academic impact, for papers by Nidhi Gupta Breakdown of academic impact, for papers by Prasanthi Karna Breakdown of academic impact, for papers by Kulthida Vaeteewoottacharn Breakdown of academic impact, for papers by Somesh Sharma Breakdown of academic impact, for papers by Ida Silvestri Breakdown of academic impact, for papers by Xiujun Liu Breakdown of academic impact, for papers by Jingwen Wang Breakdown of academic impact, for papers by İlker Dıbırdık
Rankless by CCL
2026